This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Liao, Y.-C. Articles by Lo, S. H. PubMed PubMed Citation Articles by Liao, Y.-C. Articles by Lo, S. H.

Mutations in the Focal Adhesion Targeting Region of Deleted in Liver Cancer-1 Attenuate Their Expression and Function

Center for Tissue Regeneration and Repair, Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California

Requests for reprints: Su Hao Lo, Center for Tissue Regeneration and Repair, Department of Biochemistry and Molecular Medicine, University of California, Davis, 4635 Second Avenue, Room 2000, Sacramento, CA 95817. Phone: 916-734-3656; Fax: 916-734-5750; E-mail: shlo{at}ucdavis.edu.

Key Words: DLC • focal adhesion • mutation • RhoGAP

Deleted in liver cancer-1 (DLC-1) is a RhoGTPase-activating protein (RhoGAP) domain containing tumor suppressor that is often down-regulated in various cancer types. Previously, we have shown that DLC-1 is recruited to focal adhesions by binding to the Src homology 2 domains of tensins and the focal adhesion localization is critical for the tumor suppression activity of DLC-1. To investigate whether mutations in the focal adhesion targeting (FAT) region might occur and attenuate the expression, localization, and function of DLC-1, we have first mapped the FAT region to the amino acid residues from 201 to 500, and then sequenced cDNAs and genomic DNAs encoding the FAT region from cancer patients. Several missense and nonsense mutations were detected. All missense mutations were further examined for the potential effect on the function of DLC-1. Although these mutations did not seem to affect the focal adhesion localization of DLC-1, the activities of suppressing tumor cell growth were impaired in two mutants: T301K and S308I. Consistent with the fact that the RhoGAP activity of DLC-1 is essential for inhibiting tumor cell growth, the RhoGAP activities were significantly reduced in these mutants, suggesting that the FAT region also contains a regulatory element for its COOH-terminal RhoGAP domain. Our studies have shown that mutations in DLC-1 may lead to loss of function and contribute to the tumorigenesis, and have revealed an allosteric regulation site for its RhoGAP activity. [Cancer Res 2008;68(19):7718–22]